
LOS ANGELES -- Arthritis patients taking Arcoxia (etoricoxib), an investigational highly selective Cox-2 inhibitor, had significantly fewer uncomplicated upper gastrointestinal events, versus a traditional NSAID, but it was no better for more serious GI problems.
